Trial reportJAMA oncology2015
Difference in Association of Obesity With Prostate Cancer Risk Between US African American and Non-Hispanic White Men in the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
Trial report in JAMA oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 57 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
57 citing papers in PubMed, 2 syntheses or guidelines pooled it, 105 citations in OpenAlex.
- Body mass index and prostate cancer incidence: a comprehensive systematic review.Frontiers in oncology · 2026Pooled it
- American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists · 2022Guideline
- Mass spectrometry-detected MGUS is associated with obesity and other novel modifiable risk factors in a high-risk population.Blood advances · 2024Trial
- Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trial.Endocrine-related cancer · 2022Trial
- Circadian genes and risk of prostate cancer in the prostate cancer prevention trial.Molecular carcinogenesis · 2018Trial
- DGAT1 Drives Racially Divergent Fibroblast Activation via ERK1/2-Dependent Tumorigenic Signaling in Prostate Cancer.Cancer research communications · 2026Article
- Neighborhood obesogenic factors and breast cancer risk and mortality in the Southern community cohort study.Scientific reports · 2026Article
- Prostate Cancer: Etiology, Diagnosis, and Treatment.Serican journal of medicine · 2026Article
- Obesity-linked genes may promote prostate cancer among Asian and Hispanic immigrants to North America.Frontiers in public health · 2026Review
- Cancer-Associated Cachexia in the Era of Obesity.International journal of molecular sciences · 2025Review
- Racial disparities in prostate cancer in the UK and the USA: similarities, differences and steps forwards.Nature reviews. Urology · 2025Review
- A Problem in NIH and Federally Funded Prostate Cancer Interventional Clinical Trials.Journal of racial and ethnic health disparities · 2024Article
- Association Between Obesity and Risk of Total and Obesity-Related Cancer in People With Incident Cardiovascular Disease.Journal of the American Heart Association · 2024Article
- An Assessment of Behavioral Risk Factors in Oncology Patients.Nutrients · 2024Article
- The complex interplay of modifiable risk factors affecting prostate cancer disparities in African American men.Nature reviews. Urology · 2024Review
- Involvement of Reactive Oxygen Species in Prostate Cancer and Its Disparity in African Descendants.International journal of molecular sciences · 2024Review
- PCAO2: an ontology for integration of prostate cancer associated genotypic, phenotypic and lifestyle data.Briefings in bioinformatics · 2024Article
- Body mass index, obesity and risk of prostate cancer: a systematic review and meta-analysis.Central European journal of urology · 2024Review
- General Obesity and Prostate Cancer in Relation to Abdominal Obesity and Ethnic Groups: A US Population-Based Cross-Sectional Study.Research and reports in urology · 2024Article
- The growing implications of obesity for prostate cancer risk and mortality: where do we go from here?Journal of the National Cancer Institute · 2023Article
Corrections and comments
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
8 authors at 6 institutions in 2 countries.
Funding
Abstract
importanceAfrican American men have the highest rates of prostate cancer incidence and mortality in the United States. Understanding underlying reasons for this disparity could identify preventive interventions important to African American men.
objectiveTo determine whether the association of obesity with prostate cancer risk differs between African American and non-Hispanic white men and whether obesity modifies the excess risk associated with African American race. DESIGN, SETTING, AND
participantsProspective study of 3398 African American and 22,673 non-Hispanic white men who participated in the Selenium and Vitamin E Cancer Prevention Trial (2001-2011) with present analyses completed in 2014. MAIN OUTCOMES AND MEASURES: Total, low-grade (Gleason score <7), and high-grade (Gleason score ≥7) prostate cancer incidence.
resultsWith a median (interquartile range) follow-up of 5.6 (1.8) years, there were 270, 148, and 88 cases of total, low-, and high-grade prostate cancers among African American men and a corresponding 1453, 898, and 441 cases in non-Hispanic white men, respectively. Although not associated with risk among non-Hispanic white men, BMI was positively associated with an increase in risk among African American men (BMI, <25 vs ≥35: hazard ratio [HR], 1.49 [95% CI, 0.95, 2.34]; P for trend = .03). Consequently, the risk associated with African American race increased from 28% (HR, 1.28 [95% CI, 0.91-1.80]) among men with BMI less than 25 to 103% (HR, 2.03 [95% CI, 1.38-2.98]) among African American men with BMI at least 35 (P for trend = .03). Body mass index was inversely associated with low-grade prostate cancer risk within non-Hispanic white men (BMI, <25 vs ≥35: HR, 0.80 [95% CI, 0.58-1.09]; P for trend = .02) but positively associated with risk within African American men (BMI, <25 vs ≥35: HR, 2.22 [95% CI, 1.17-4.21]; P for trend = .05). Body mass index was positively associated with risk of high-grade prostate cancer in both non-Hispanic white men (BMI, <25 vs ≥35: HR, 1.33 [95% CI, 0.90-1.97]; P for trend = .01) and African American men, although the increase may be larger within African American men, albeit the racial interaction was not statistically significant (BMI, <25 vs ≥35: HR, 1.81 [95% CI, 0.79-4.11]; P for trend = .02). CONCLUSIONS AND RELEVANCE: Obesity is more strongly associated with increased prostate cancer risk among African American than non-Hispanic white men and reducing obesity among African American men could reduce the racial disparity in cancer incidence. Additional research is needed to elucidate the mechanisms underlying the differential effects of obesity in African American and non-Hispanic white men.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.